Evaluation of KX2-391 in Patients With Advanced Malignancies
The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.
Solid Tumors|Lymphoma
DRUG: KX2-391
Determine maximum tolerated dose of the drug, 64 days
Pharmacokinetics, Pharmacodynamics, Efficacy, 64 days
The purpose of this first in human study is to determine the safety and pharmacokinetics of KX2-391 in patients with solid tumors and lymphoma, who are refractory to conventional cancer treatments. In addition, pharmacodynamics will be evaluated using biomarkers in peripheral blood mononuclear cells and in tissue biopsy samples.